Synergistic Effect of Sorafenib and Radiation on Human Oral Carcinoma in vivo

NCUIR > college of Health Sciences and Technology > Department of Life Science > journal & Dissertation > Item 987654321/102630

Please use this identifier to cite or link to this item: https://ir.lib.ncu.edu.tw/handle/987654321/102630

Title:	Synergistic Effect of Sorafenib and Radiation on Human Oral Carcinoma in vivo
Authors:	許斐婷;Hsu, Fei-Ting;Chang, Betty;Chen, John Chun-Hao;Chiang, I-Tsang;Liu, Yu-Chang;Kwang, Wei-Kang;Hwang, Jeng-Jong
Contributors:	生醫理工學院生命科學系
Keywords:	13/109;14/63;45/41;59/5;631/67/1059/602;631/67/1665;631/67/2321;64/60;82/51;82/80;96/2;96/95;Animals;Apoptosis - drug effects;Apoptosis - radiation effects;Bone Neoplasms - drug therapy;Bone Neoplasms - genetics;Bone Neoplasms - pathology;Bone Neoplasms - radiotherapy;Carcinoma, Squamous Cell - drug therapy;Carcinoma, Squamous Cell - genetics;Carcinoma, Squamous Cell - pathology;Carcinoma, Squamous Cell - radiotherapy;Cell Proliferation - drug effects;Cell Proliferation - radiation effects;Combined Modality Therapy;Computed tomography;Deoxyribonucleic acid;DNA;Gene Expression Regulation, Neoplastic - drug effects;Gene Expression Regulation, Neoplastic - radiation effects;Humanities and Social Sciences;Humans;Inhibitor drugs;Mandible;Mice;Mouth Neoplasms - drug therapy;Mouth Neoplasms - genetics;Mouth Neoplasms - pathology;Mouth Neoplasms - radiotherapy;multidisciplinary;NF-kappa B - biosynthesis;Niacinamide - administration & dosage;Niacinamide - analogs & derivatives;Oral cancer;Oral carcinoma;Oral squamous cell carcinoma;Phenylurea Compounds - administration & dosage;Quality of life;Radioresistance;Rodents;Science;Squamous cell carcinoma;Synergistic effect;Targeted cancer therapy;Tumorigenesis;Tumors;Xenograft Model Antitumor Assays
Date:	2015-10-21
Issue Date:	2026-04-23 11:13:55 (UTC+8)
Publisher:	Nature Publishing Group;London: Nature Publishing Group UK
Abstract:	摘要： Oral squamous cell carcinoma often causes bone invasion resulting in poor prognosis and affects the quality of life for patients. Herein, we combined radiation with sorafenib, to evaluate the combination effect on tumor progression and bone erosion in an in situ human OSCC-bearing mouse model. Treatment procedure were arranged as following groups: (a) normal (no tumor); (b) control (with tumor); (c) sorafenib (10 mg/kg/day); (d) radiation (single dose of 6 Gy); (e) pretreatment (sorafenib treatment for 3 days prior to radiation) and (f) concurrent treatment (sorafenib and radiation on the same day). The inhibition of tumor growth and expression level of p65 of NF-κB in tumor tissues were the most significant in the pretreatment group. EMSA and Western blot showed that DNA/NF-κB activity and the expressions of NF-κB-associated proteins were down-regulated. Notably, little to no damage in mandibles and zygomas of mice treated with combination of sorafenib and radiation was found by micro-CT imaging. In conclusion, sorafenib combined with radiation suppresses radiation-induced NF-κB activity and its downstream proteins, which contribute to radioresistance and tumorigenesis. Additionally, bone destruction is also diminished, suggesting that combination treatment could be a potential strategy against human OSCC. 其他題名： Sci Rep 出版者： London: Nature Publishing Group UK 出版日期： 2015-10-21 出處： Scientific reports, 2015-10, Vol.5 (1), p.15391, Article 15391 資源來源： Publicly available content database 版權： The Author(s) 2015 版權： Copyright Nature Publishing Group Oct 2015 版權： Copyright © 2015, Macmillan Publishers Limited 2015 Macmillan Publishers Limited 識別號： ISSN: 2045-2322 識別號： EISSN: 2045-2322 識別號： DOI: 10.1038/srep15391 識別號： PMID: 26487364
Appears in Collections:	[Department of Life Science] journal & Dissertation

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	9	View/Open

社群 sharing

Loading...